Please use this identifier to cite or link to this item:
https://olympias.lib.uoi.gr/jspui/handle/123456789/7814Full metadata record
| DC Field | Value | Language |
|---|---|---|
| dc.contributor.author | Yavropoulou, M. P. | en |
| dc.contributor.author | Kotsa, K. | en |
| dc.contributor.author | Gotzamani Psarrakou, A. | en |
| dc.contributor.author | Papazisi, A. | en |
| dc.contributor.author | Tranga, T. | en |
| dc.contributor.author | Ventis, S. | en |
| dc.contributor.author | Yovos, J. G. | en |
| dc.date.accessioned | 2015-11-24T16:34:32Z | - |
| dc.date.available | 2015-11-24T16:34:32Z | - |
| dc.identifier.issn | 1109-3099 | - |
| dc.identifier.uri | https://olympias.lib.uoi.gr/jspui/handle/123456789/7814 | - |
| dc.rights | Default Licence | - |
| dc.subject | Adult | en |
| dc.subject | Biological Markers/blood | en |
| dc.subject | Bone Density Conservation Agents/*adverse effects | en |
| dc.subject | Calcifediol/blood | en |
| dc.subject | Calcium/blood | en |
| dc.subject | Female | en |
| dc.subject | Fibroblast Growth Factors/blood | en |
| dc.subject | Humans | en |
| dc.subject | Hydroxycholecalciferols/*adverse effects | en |
| dc.subject | Hyperparathyroidism, Secondary/blood/chemica | en |
| dc.title | Cinacalcet in hyperparathyroidism secondary to X-linked hypophosphatemic rickets: case report and brief literature review | en |
| heal.type | journalArticle | - |
| heal.type.en | Journal article | en |
| heal.type.el | Άρθρο Περιοδικού | el |
| heal.identifier.secondary | http://www.ncbi.nlm.nih.gov/pubmed/20688626 | - |
| heal.language | en | - |
| heal.access | campus | - |
| heal.recordProvider | Πανεπιστήμιο Ιωαννίνων. Σχολή Επιστημών και Τεχνολογιών. Τμήμα Βιολογικών Εφαρμογών και Τεχνολογιών | el |
| heal.publicationDate | 2010 | - |
| heal.abstract | X-linked dominant hypophosphatemic rickets (XLH) is the most prevalent genetic form of hypophosphatemic rickets. Standard treatment of XLH patients includes long-term administration of phosphate and calcitriol. Treated patients usually respond well to the conventional therapy and demonstrate amelioration of rachitic symptoms and improved growth. However, long-term administration of phosphate and vitamin D preparations is sometimes complicated with nephrocalcinosis, secondary or tertiary hyperparathyroidism and arterial hypertension. We describe a patient with XLH, caused by a rare missense mutation of the PHEX gene. The patient, while under treatment with alphacalcidol and oral phosphate, developed hypercalciuria, nephrocalcinosis, secondary hyperparathyroidism and arterial hypertension. Cinacalcet was added to the therapeutic regimen and the long-term effects on calciotropic parameters and FGF23 levels are herein reported. | en |
| heal.journalName | Hormones (Athens) | en |
| heal.journalType | peer reviewed | - |
| heal.fullTextAvailability | TRUE | - |
| Appears in Collections: | Άρθρα σε επιστημονικά περιοδικά ( Ανοικτά) | |
Files in This Item:
There are no files associated with this item.
This item is licensed under a Creative Commons License
